Results 131 to 140 of about 53,461 (270)

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 139-149, July 2026.
We compared the initial efficacy of denosumab (Dmab) and zoledronate (ZOL) in treatment‐naive patients with osteoporosis. This cohort study, based on TriNetX data, evaluated the risks of fractures and mortality using Kaplan–Meier survival analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs).
Ko‐Hsiu Lu   +2 more
wiley   +1 more source

Comparison of osteoporosis frequency in female patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis [PDF]

open access: yes
Objective: The aim of this study is to determine of the frequency of osteoporosis in patient with non-radiographic axial spondyloarthritis (SpA) and ankylosing spondilitis.
Şükran Erten, Bekir Torun
core   +1 more source

Transthoracic Echocardiography findings in patients with Ankylosing Spondylitis in Kurdistan region

open access: yesAdvanced Medical Journal
Background and objectives: Ankylosing spondylitis is a chronic inflammatory disorder that affecting axial and non-axial joints leads to a loss of mobility and function over time.
Elaf Kamal Abdulwahab   +1 more
doaj   +1 more source

Relationship Between Central Sensitization and Genetic Polymorphisms—A Case–Control Study in Fibromyalgia

open access: yesEuropean Journal of Pain, Volume 30, Issue 6, July 2026.
ABSTRACT Background Fibromyalgia is a syndrome characterised by widespread chronic pain, which is believed to be mediated by a state of central sensitisation (CS). Based on the hypothesis that CS itself could have genetic determinants, our aim was to further explore this pathway.
Nicolas Macian   +8 more
wiley   +1 more source

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience

open access: yesLiver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background We aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD). Methods Using the Drug‐Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non‐IBD indications (but excluding ...
Harish Gopalakrishna   +9 more
wiley   +1 more source

Needing to be Normal: Understanding the Experiences and Barriers of Young Men with Ankylosing Spondylitis

open access: yes, 2013
Graeme Kohler BSc. (Health Education), MA (Health Promotion) School of Health and Human Performance, Dalhousie University Objective: To understand the experiences of young men living with Ankylosing Spondylitis (AS).
Kohler, Graeme Patrick
core  

Positive and Negative Cardiovascular Effects of JAK Inhibitors in Inflammation

open access: yesACR Open Rheumatology, Volume 8, Issue 6, June 2026.
Chronic inflammation, characteristic of many autoimmune diseases, such as rheumatoid arthritis (RA), or myeloproliferative neoplasms (MPNs), is an independent driver of accelerated cardiovascular (CV) risk, primarily through proinflammatory cytokines that induce atherosclerosis and endothelial dysfunction.
Aliki Zavoriti, Pierre Miossec
wiley   +1 more source

Artificial Intelligence for Bone: Theory, Methods, and Applications

open access: yesAdvanced Intelligent Discovery, Volume 2, Issue 3, June 2026.
Advances in artificial intelligence (AI) offer the potential to improve bone research. The current review explores the contributions of AI to pathological study, biomarker discovery, drug design, and clinical diagnosis and prognosis of bone diseases. We envision that AI‐driven methodologies will enable identifying novel targets for drugs discovery. The
Dongfeng Yuan   +3 more
wiley   +1 more source

Disease Remission: A Scoping Review With Thematic Analysis of the Scientific Literature With Implications for Chronic Rhinosinusitis

open access: yesInternational Forum of Allergy &Rhinology, Volume 16, Issue 6, Page 615-629, June 2026.
ABSTRACT Background Remission, a term used to describe a goal of treatment for some chronic diseases, has recently been proposed for chronic rhinosinusitis (CRS). However, it is unclear what remission means for CRS and why it should serve as a goal in the present‐day treatment of CRS.
Nikhil Parail   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy